Abstract
Immune checkpoint inhibitors (ICIs) have been widely used in non-small cell lung cancer with wildtype EGFR/ALK genes. However, the effect of ICIs on advanced NSCLC with EGFR genes sensitive mutations has been controversial. There are no reports on whether ICIs monotherapy can be used in the treatment of NSCLC with EGFR sensitive mutations. A patient with metastatic lung squamous cell carcinoma with EGFR G719s mutations, high PD-L1 score and a tuberculosis history was given first-line treatment of afatinib, camrelizumab monotherapy (200 mg, intravenous, once every three weeks) from February 24,2020 to January 2023. The patient achieved partial response (PR) after treatment with camrelizumab. The progress-free survival (PFS) due to camrelizumab monotherapy was more than 34 months.It is concluded that camrelizumab has promising potential effectiveness as a treatment option for lung squamous cell cancer with EGFR G719 mutations and high PD-L1 score.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
